Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a combination of three antimicrobial agents: amoxicillin (a penicillin-type antibiotic), clavulanic acid (a beta-lactamase inhibitor), and cefotiam (a cephalosporin antibiotic). While amoxicillin + clavulanic acid is a well-established combination used to treat various bacterial infections including those of the ears, lungs, sinuses, skin, and urinary tract, the addition of cefotiam to this combination is not documented in the provided search results. Amoxicillin works by stopping bacterial growth, while clavulanic acid prevents bacteria from destroying amoxicillin by inhibiting beta-lactamase enzymes. Cefotiam would likely provide additional coverage against certain bacteria as a cephalosporin antibiotic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clavulanic acid + cefotiam.